Article
Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland.
BMJ open - 6 Nov 2019
Sutherland C Simone, Ademi Zanfina, Michaud Joëlle, Schur Nadine, Lingg Myriam, Bhadhuri Arjun, Pache Thierry D, Bitzer Johannes, Suchon Pierre, Albert Valerie, Hersberger Kurt E, Tanackovic Goranka, Schwenkglenks Matthias
Abstract excerpt
AIM: The aim of this study was to assess the cost effectiveness of the Pill Protect (PP) genetic screening test for venous thromboembolism (VTE) risk compared with standard of care (SoC), for women considering combined hormonal contraceptives (CHCs) in Switzerland. METHODS: A two-part microsimulation model was developed to estimate VTE events, costs and quality-adjusted life years (QALYs) associated with the PP...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.